Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal mitoxantrone + venetoclax + azacitidine versus venetoclax + azacitidine for relapsed/refractory acute myeloid leukemia
ChiCTR2400084237Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mitoxantrone hydrochloride liposome, venetoclax and azacitidine in acute myeloid leukemia (AML) (2 arms), sponsored by Tongji Hospital. Primary endpoint: Composite remission rate after one course. Planned start May 2024; status: not yet recruiting.
02
Drugs
mitoxantrone hydrochloride liposomevenetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2400084237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084237.